使用验证的HPTLC方法同时估计生物活性标记物,并评估HEPASAVE的肝保护作用:一种阿育吠陀配方
Dipal M Gandhi1, Kriti H Sharma2, Aakash Kumar S3
1Department of Pharmacognosy, Institute of Pharmacy, Nirma University, Ahmedabad 382481, Gujarat, India.
Fitoterapia
|April 21, 2025
概括
一种新的HPTLC方法精确量化了HEPASAVE糖中的andrographolide,酸和kutkin. 这种经过验证的方法确保了可重复性,并证明了配方.
科学领域:
- 植物化学 植物化学
- 分析化学 分析化学
- 艾尔韦达医学是一种医药.
背景情况:
- 阿育吠陀配方需要精确的质量控制,以保持一致的疗效.
- 关键的生物活性化合物如andrographolide,酸和kutkin对于许多传统药物的治疗性质至关重要.
- 精确量化这些标记物可确保草药产品的安全性和有效性.
研究的目的:
- 开发和验证一种高性能薄层染色学 (HPTLC) 方法,用于同时估计安德罗格拉 (AG),酸 (GA) 和库特金 (KT2).
- 在阿育吠陀配方HEPASAVE糖中量化这三个生物标志物.
- 评估开发的HPTLC方法的可复制性和准确性.
主要方法:
- 高性能薄层染色学 (HPTLC) 方法的开发和验证.
- 静止阶段: 60F254凝预涂TLC板. 静止阶段: 60F254凝预涂TLC板.
- 移动阶段:托卢烯:乙酸乙烯:酸:甲醇 (3:3:0.8:0.4,v/v/v/v).
- 检测:使用Camag TLC扫描仪III在254 nm的光谱密度计扫描.
主要成果:
- 通过HPTLC方法实现了AG,GA和KT2的紧点,Rf值分别为0.74,0.66和0.21.
- 在指定度范围内观察到AG (r2=0.995),GA (r2=0.993) 和KT2 (r2=0.992) 的优异线性.
- 在HEPASAVE糖中的量化量为AG的1.27%w/v,GA的1.15%w/v和KT2.014%w/v.
- 该方法被证明是可重复的,用于同时定量.
结论:
- 一种精确,可复制和验证的HPTLC方法可以同时量化HEPASAVE糖中的andrographolide,酸和kutkin.
- 开发的方法确保了阿育吠陀配方的质量控制.
- 该研究还表明,HEPASAVE糖在动物模型中显著降低了SGPT,SGOT和ALP水平,这表明肝保护作用.
更多相关视频
相关概念视频
Hepatic Drug Clearance: Effect of Protein Binding
129
Hepatic clearance is influenced by protein binding based on the drug's extraction ratio. Drugs with high extraction ratios are considered flow-limited and remain unaffected by protein binding during hepatic clearance. On the other hand, drugs with low extraction ratios may be impacted by plasma protein binding, although the extent of this influence depends on the fraction of the drug bound.
For low-extraction-ratio drugs that are less than 80% protein-bound, minor changes in protein binding...
For low-extraction-ratio drugs that are less than 80% protein-bound, minor changes in protein binding...
129
Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance
23
Drug transporters are critical in drug absorption, distribution, and excretion processes. They should be included in physiological-based pharmacokinetic (PBPK) models, which help predict human drug disposition. However, predicting this is challenging during drug development, especially when liver transport is involved. However, with a realistic representation of body transport processes, an accurate model may be possible.
A recent model describes pravastatin's hepatobiliary excretion,...
A recent model describes pravastatin's hepatobiliary excretion,...
23


